Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428711 | 0.94 | GRM2 (0.51) | ERN1HPGDALDH1A1LMNATSHR | |
| SCHEMBL31429007 | 0.89 | CCNC (0.56) | ERN1JAK2 | |
| SCHEMBL31428671 | 0.89 | HPGD (0.50) | ERN1HPGDALDH1A1LMNATSHR | |
| SCHEMBL31428784 | 0.87 | MAPT (0.52) | ERN1HPGDALDH1A1LMNAMEN1 | |
| SCHEMBL31428608 | 0.87 | ACACB (0.43) | ERN1HPGDALDH1A1 | |
| SCHEMBL31428712 | 0.86 | GRM2 (0.49) | ERN1HPGDALDH1A1GRM2 | |
| SCHEMBL31428979 | 0.86 | HPGD (0.51) | ERN1HPGDALDH1A1LMNATSHR | |
| SCHEMBL24977229 | 0.85 | GRM2 (0.48) | ERN1HPGDALDH1A1MEN1RAB9A | |
| SCHEMBL31428605 | 0.85 | GRM2 (0.48) | ERN1HPGDALDH1A1MEN1RAB9A | |
| SCHEMBL24975788 | 0.85 | ERN1 (0.48) | ERN1HPGDMEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | ERN1 1375/4885HPGD 4233/4885ALDH1A1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.